immatics biotechnologies GmbH – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "immatics biotechnologies GmbH - Product Pipeline Review - 2012" provides data on the immatics biotechnologies GmbH's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, immatics biotechnologies GmbH's corporate website, SEC filings, investor presentations and featured press releases, both from immatics biotechnologies GmbH and industry-specific third party sources, put together by our team.
Scope
- immatics biotechnologies GmbH - Brief immatics biotechnologies GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of immatics biotechnologies GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of immatics biotechnologies GmbH with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the immatics biotechnologies GmbH's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate immatics biotechnologies GmbH's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of immatics biotechnologies GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the immatics biotechnologies GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with immatics biotechnologies GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of immatics biotechnologies GmbH and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
immatics biotechnologies GmbH Snapshot
immatics biotechnologies GmbH Overview
Key Information
Key Facts
immatics biotechnologies GmbH – Research and Development Overview
Key Therapeutic Areas
immatics biotechnologies GmbH – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
immatics biotechnologies GmbH – Pipeline Products Glance
immatics biotechnologies GmbH – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
immatics biotechnologies GmbH Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
immatics biotechnologies GmbH – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
immatics biotechnologies GmbH – Drug Profiles
IMA-901
Product Description
Mechanism of Action
R&D Progress
IMA-910
Product Description
Mechanism of Action
R&D Progress
IMA-930
Product Description
Mechanism of Action
R&D Progress
IMA-942
Product Description
Mechanism of Action
R&D Progress
IMA-950
Product Description
Mechanism of Action
R&D Progress
IMA910 + Leukine
Product Description
Mechanism of Action
R&D Progress
immatics biotechnologies GmbH – Pipeline Products by Route of Administration
immatics biotechnologies GmbH – Pipeline Products By Mechanism of Action
immatics biotechnologies GmbH – Recent Pipeline Updates
immatics biotechnologies GmbH – Locations And Subsidiaries
Head Office
immatics biotechnologies GmbH, Recent Developments
immatics biotechnologies GmbH- Press Release
Jul 29, 2012: immatics Announces Publication Of IMA901 Cancer Vaccine Data In Nature Medicine
Jun 01, 2012: immatics Presents Encouraging Overall Survival Data From Phase II Study In Advanced Colorectal Cancer At ASCO Annual Meeting
May 25, 2012: immatics Presents Data On IMA910 At ASCO Annual Meeting
Jan 24, 2012: immatics Presents Positive Phase II Results With IMA910 In Patients With Advanced Colorectal Cancer At ASCO Gastrointestinal Cancers Symposium
Financial Deals Landscape
immatics biotechnologies GmbH, Deals Summary
immatics biotechnologies GmbH, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
immatics biotechnologies Secures $70.3 Million In Series C Financing
Immatics Biotechnologies Secures $51.96 Million In Series B Financing
Private Equity
Immatics Biotechnologies Raises $54.74 Million In Private Equity Financing
Partnerships
Scancell Holdings Enters Into Research Agreement With immatics biotechnologies
immatics biotechnologies Enters Into Co-Development With Cancer Research
immatics biotechnologies Enters Into Research Agreement With responsif
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
immatics biotechnologies GmbH, Key Information
immatics biotechnologies GmbH, Key Facts
immatics biotechnologies GmbH – Pipeline by Indication, 2012
immatics biotechnologies GmbH – Pipeline by Stage of Development, 2012
immatics biotechnologies GmbH – Monotherapy Products in Pipeline, 2012
immatics biotechnologies GmbH – Combination Treatment Modalities in Pipeline, 2012
immatics biotechnologies GmbH – Phase III, 2012
immatics biotechnologies GmbH – Phase II, 2012
immatics biotechnologies GmbH – Phase I, 2012
immatics biotechnologies GmbH – Pre-Clinical, 2012
immatics biotechnologies GmbH – Pipeline By Route of Administration, 2012
immatics biotechnologies GmbH – Pipeline Products By Mechanism of Action, 2012
immatics biotechnologies GmbH – Recent Pipeline Updates, 2012
immatics biotechnologies GmbH, Deals Summary
immatics biotechnologies Secures $70.3 Million In Series C Financing
Immatics Biotechnologies Secures $51.96 Million In Series B Financing
Immatics Biotechnologies Raises $54.74 Million In Private Equity Financing
Scancell Holdings Enters Into Research Agreement With immatics biotechnologies
immatics biotechnologies Enters Into Co-Development With Cancer Research
immatics biotechnologies Enters Into Research Agreement With responsif
List of Figures
immatics biotechnologies GmbH – Pipeline by Indication, 2012
immatics biotechnologies GmbH – Pipeline by Stage of Development, 2012
immatics biotechnologies GmbH – Monotherapy Products in Pipeline, 2012
immatics biotechnologies GmbH – Combination Treatment Modalities in Pipeline, 2012
immatics biotechnologies GmbH - Pipeline Products By Mechanism of Action, 2012 24